当前位置:
X-MOL 学术
›
Ther. Adv. Med. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2019-11-14 , DOI: 10.1177/1758835919887044 Emily M. Miller 1 , Lee S. Schwartzberg 2
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2019-11-14 , DOI: 10.1177/1758835919887044 Emily M. Miller 1 , Lee S. Schwartzberg 2
Affiliation
Over the past 10 years, biological medications have become increasingly common in the treatment of cancers and immunological diseases. With regard to breast cancer specifically, trastuzumab was approved by the US Food and Drug Administration (FDA) for use in HER2-overexpressing breast cancer, based on evidence of improved overall survival (OS) in both early stage and metastatic breast cancer.1,2 However, this revolutionary addition to breast cancer therapy comes at a high cost, with some estimates reaching at least US$70,000 for 1 year of therapy in the US.3,4 Often, financial factors, including reimbursement, out-of-pocket costs, and administrative factors are barriers to patient access for this recommended treatment.
中文翻译:
乳腺癌生物仿制药:美国针对HER2的抗体综述
在过去的十年中,生物药物在癌症和免疫疾病的治疗中变得越来越普遍。特别是针对乳腺癌,曲妥珠单抗已获美国食品和药物管理局(FDA)批准用于过表达HER2的乳腺癌,这是基于早期和转移性乳腺癌总体生存率(OS)均得到改善的证据。1,2但是,这种革命性的乳腺癌治疗方法成本很高,据估计,在美国治疗1年的费用至少达到70,000美元。3,4通常,财务因素(包括报销,自付费用和管理因素)是使患者无法获得此推荐治疗的障碍。
更新日期:2019-11-14
中文翻译:
乳腺癌生物仿制药:美国针对HER2的抗体综述
在过去的十年中,生物药物在癌症和免疫疾病的治疗中变得越来越普遍。特别是针对乳腺癌,曲妥珠单抗已获美国食品和药物管理局(FDA)批准用于过表达HER2的乳腺癌,这是基于早期和转移性乳腺癌总体生存率(OS)均得到改善的证据。1,2但是,这种革命性的乳腺癌治疗方法成本很高,据估计,在美国治疗1年的费用至少达到70,000美元。3,4通常,财务因素(包括报销,自付费用和管理因素)是使患者无法获得此推荐治疗的障碍。